1. Home
  2. R&D for Health Products

R&D for Health Products

Including in Emergencies and Neglected

The challenges of decentralising vaccine production to Africa
TB has reclaimed its place as the world’s biggest infectious killer – but are its days numbered?
WHO Updates List of Most Threatening Drug-Resistant Bacteria as Pharma Warns New Antibiotic Pipeline is Inadequate
Antibacterial innovation: parachutes needed
WHO target product profiles: four diagnostic tests needed in the effort to eliminate African trypanosomiasis
Building Africa's first mRNA vaccine facility
As pandemic raged, global south lacked vaccines. Never again, researchers vow.
A pandemic treaty for equitable global access to medical countermeasures: seven recommendations for sharing intellectual property, know-how and technology
Discussion Paper on IP and Access to Publicly Funded Research Results in Health Emergencies. Publicly Funded International R&D Projects
Exclusive: Updated Pandemic Accord Draft Sees Watered Down Text on Publicly-Funded R&D; Pathogen Access and ‘Benefit Sharing’ Linkage Remain
Opportunities and challenges of leveraging COVID-19 vaccine innovation and technologies for developing sustainable vaccine manufacturing capabilities in Africa
COVID-19 vaccines and the pandemic: lessons learnt for other neglected diseases and future threats
Towards a reformed research and development ecosystem for infectious disease
Subscribe to R&D for Health Products